Food
Aachen, Germany, 21 September 2026 Grünenthal, a worldwide leader in discomfort management and research study, today revealed a contract with Bayer AG to get Stivarga ®, an oral treatment for particular innovative cancers, for approximately 375 million. The acquisition goes through traditional closing conditions, consisting of approval by the appropriate regulative authorities. The acquisition is anticipated to nearby completion of 2026 or early 2027.
Stivarga ® (regorafenib) is an oral multkinase inhibitor suggested for metastatic colorectal cancer, hepatocellular cancer and intestinal stromal tumours (GIST) in clients who have actually currently been treated with, or who can not be provided, other offered treatments. It is authorized and readily available in more than 90 markets worldwide.
“This acquisition is a strong strategic fit for Grünenthal and reflects our disciplined M&A strategy of acquiring established medicines that address clear and ongoing medical needs and create long-term value,” stated Gabriel Baertschi, CEO, Grünenthal. “Stivarga® has a well-established role in patient care and the transaction is immediately accretive to our business. By leveraging the strength of our commercial and operational expertise, we see clear opportunities to maximise the value of the medicine and support Grünenthal’s long-term growth.”
Loss of exclusivity for Stivarga ® is expected in 2029 in the European Union and in 2030 in the United States (United States). Grünenthal approximates that Stivarga ® might contribute a favorable effect on its combined EBITDA of approximately around 100 million for the year ending 31 December 2027, based upon an analysis of the info offered to Grünenthal from Bayer and presuming closing by the end of 2026 or the start of 2027, in addition to a full-year combination.
The acquisition is the current advancement in Grünenthal’s M&A technique and follows the effective combination of a number of essential medications throughout a variety of health conditions, consisting of the international rights to Nebido, the rights to Cialis ® in Mexico, Brazil and Colombia, the European rights to Crestor and Nexium, and the international rights to Vimovo (ex-US and Japan), Zomig (ex-Japan) and Qutenza. In addition to possession acquisitions, previously this year, Grünenthal obtained complete ownership of Grünenthal Meds, a formerly joint endeavor with Kyowa Kirin International to market its recognized medications portfolio, and, in 2024, got the United States business Valinor Pharma and the item Movantik ®. The business has actually invested around 2.6 billion in effective M&A deals given that 2017.
About Stivarga ®
Stivarga ® is a once-daily, oral prescription medication for specific sophisticated cancers. It has actually dealt with more than one million clients throughout more than 90 nations over 10 years.
In the EU, Stivarga ® is suggested as monotherapy for the treatment of adult clients with metastatic colorectal cancer (mCRC) who have actually been formerly treated with, or are ruled out prospects for, readily available treatments consisting of fluoropyrimidine-based chemotherapy, an anti-VEGF treatment and an anti-EGFR treatment, in addition to for the treatment of adult clients with unresectable or metastatic intestinal stromal growth (GIST) who advanced on or are intolerant to previous treatment with imatinib and sunitinib, and for the treatment of adult clients with hepatocellular cancer (HCC) who have actually been formerly treated with sorafenib.
In the United States, Stivarga ® is suggested for the treatment of clients with mCRC who have actually been formerly treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF treatment, and, if RAS wild-type, an anti-EGFR treatment, along with in your area advanced, unresectable or metastatic GIST who have actually been formerly treated with imatinib mesylate and sunitinib malate, and for HCC who have actually been formerly treated with sorafenib.
About Grünenthal
Grünenthal is an international leader in discomfort management and associated illness. As a science-based, completely incorporated pharmaceutical business, we have a long performance history of bringing ingenious treatments and modern innovations to clients worldwide. Our function is to alter lives for the much better and development is our enthusiasm. We focus all our activities and efforts on working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 nations throughout Europe, Latin America, and the U.S. Our items are offered in approx. 100 nations. In 2025, Grünenthal utilized around 4,100 individuals and attained incomes of 1.8 billion.
More details: www.grunenthal.com
Follow us on LinkedIn & Instagram
Advisors
Freshfields acted as legal counsel to Grünenthal.
Contact Information
Matt Crabb
Grünenthal Group
—
Contact United States
Discover more from PMN S.P.O.R.T.S - A PRIME MEDIA NETWORK BRAND
Subscribe to get the latest posts sent to your email.
